|
|
|
|
Kathleen M. Morrow, PhD
Kathleen Morrow, PhD, is an Assistant Professor of Psychiatry and Human Behavior at Brown Medical School and The Miriam Hospital. She received her doctorate in clinical psychology from Western Michigan University in 1996 and completed an NIAAA postdoctoral research fellowship at the Center for Alcohol and Addiction Studies at Brown University. Her research interests focus on behavioral HIV and STD prevention interventions, as well as product acceptability research of newly developed vaginal microbicides designed to provide woman-initiated HIV prevention options. Her work, conducted both domestically and internationally, incorporates traditional quantitative evaluation, as well as qualitative data collection and analysis.
A Contextual Model of Microbicide Acceptability,
NIMH
Buck, J.M., Morrow, K.M., Margolis, A., Eldridge, G., Sosman, J., Binson, D., MacGowan, R, Kacanek, D, Flanigan, TP, & The Project START Study Group. (in press). Hepatitis B vaccination in prison: The perspectives of formerly incarcerated men. Journal of Correctional Health Care. El-Sadr, WM, Mayer, KH, Maslanowski, L, Hoesley, C, Justman, J, Gai, F,
Mauck, C, Absalon, J, Carballo-Dieguez, A, Morrow, K, Msse, B,
Soto-Torres, L & Kwiecien, A for the HIV Prevention Trials Network (HPTN) 049
Protocol Team. (in press). Safety and Acceptability of Cellulose Sulfate as a
Vaginal Microbicide in HIV-infected Women. AIDS. Dr. Morrow was the
Chair of the Acceptability Substudy for this project and is the only
acceptability investigator in the author group. Grinstead, O., Faigeles, B., Comfort, M.,
Seal, D., Nealey-Moore, J., Belcher, L., Morrow, K. and the Project
Start Study Group. (2005). HIV, STD, and hepatitis risk to primary female
partners of men being released from prison. Women and Health, 41,
63-80. Morrow, K., Costello, T. (2004). HIV, STD and Hepatitis Prevention
among Women in Methadone Maintenance: A Qualitative and Quantitative Needs
Assessment. AIDS Care, (16) 4, 426-433. Grinstead O, Seal DW, Wolitski R, Flanigan T, Fitzgerald C, Nealey-Moore J,
Askew J, and the Project START Study Group*. (2003). HIV and STD
testing in prisons: perspectives of in-prison service providers. AIDS
Education and Prevention, 15, 547-560.
*Morrow was the Principal Investigator for the Rhode Island site. Seal DW, Margolis AD, Sosman J, Kacanek D, Binson D, and the Project START Study Group* (2003). HIV and STD Risk Behavior among 18-25 Year Old Men Released From U.S. Prisons: Provider Perspectives. AIDS & Behavior, 7(2), 131-141. *Dr. Morrow was the Principal Investigator for the Rhode Island site. Morrow, K., Rosen, R., Richter, L., Emans, A., Forbes, A., Day, J., Morar, N., Maslankowski, L., Profy, A.T., Kelly, C., Abdool Karim, S., & Mayer, K. (2003). The acceptability of an investigational vaginal microbicide, PRO 2000 Gel in the context of a Phase I clinical trial. Journal of Women's Health, 12(7), 655-666. Morrow, K., Costello, T., & Boland, R. (2001). Understanding the psychosocial needs of HIV-positive women: A qualitative study. Psychosomatics, 42, 497-503. Bentley, M.,
Morrow, K., Fullem, A., Chesney, M., Horton, S., Rosenberg, Z., &
Mayer, K. (2000). Acceptability of a potential vaginal microbicide, Buffergel,
during a phase I safety trial among low-risk women in Rhode Island. Family
Planning Perspectives, 32(4), 184-188. Osowiecki, D., Cohen, R., Morrow, K., Flanigan, T., & Boland, R. (2000). Neurocognitive and psychological contributions to quality of life in HIV-1 infected women. AIDS, 14, 1327-1332
|
|
|
|